Faculty & Research
Publications
Publications
  • December 1992 (Revised September 1996)
  • Case
  • HBS Case Collection

ImmuLogic Pharmaceutical Corporation (Abridged)

By: Josh Lerner
  • Format:Print
  • | Pages:25
ShareBar

Abstract

ImmuLogic Pharmaceutical Corp., a development-stage biotechnology company, is considering making an initial offering of common stock. The rationales for and problems of high-technology start-ups are explored. The challenges posed by "windows" for public offerings are highlighted.

Keywords

Decisions; Initial Public Offering; Entrepreneurship; Going Public; Business Startups; Biotechnology Industry; Pharmaceutical Industry; United States

Citation

Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (Abridged)." Harvard Business School Case 293-087, December 1992. (Revised September 1996.)

About The Author

Josh Lerner

Entrepreneurial Management
More Publications

More from the Author